Compare SMG & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMG | PHVS |
|---|---|---|
| Founded | 1868 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.4B |
| IPO Year | 2012 | 2020 |
| Metric | SMG | PHVS |
|---|---|---|
| Price | $59.47 | $32.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | ★ $72.83 | $57.68 |
| AVG Volume (30 Days) | ★ 1.0M | 594.6K |
| Earning Date | 11-04-2026 | 11-11-2026 |
| Dividend Yield | ★ 4.45% | N/A |
| EPS Growth | ★ 504.92 | N/A |
| EPS | ★ 3.82 | N/A |
| Revenue | ★ $3,016,500,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.23 | N/A |
| P/E Ratio | $15.50 | ★ N/A |
| Revenue Growth | ★ 6.17 | N/A |
| 52 Week Low | $47.90 | $21.02 |
| 52 Week High | $75.34 | $43.25 |
| Indicator | SMG | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 68.32 | 53.58 |
| Support Level | $58.59 | $31.51 |
| Resistance Level | $63.66 | $32.83 |
| Average True Range (ATR) | 1.74 | 1.27 |
| MACD | 1.09 | 0.42 |
| Stochastic Oscillator | 95.23 | 95.87 |
Scotts Miracle-Gro is the largest purveyor of home lawn and gardening products in the US. The company sells a broad range of lawncare products, including grass seed, fertilizer, and lawn-related weed, animal, and disease control. US consumer typically generates the vast majority of companywide revenue and profits. Its lawncare and gardening products are well-recognized brands in the US, including Scotts, Miracle-Gro, Roundup, Ortho, and Tomcat. Over half of revenue typically comes from Home Depot and Lowe's, as Scotts' products are featured at both home improvement retailers.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.